|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007134,
umls-concept:C0021149,
umls-concept:C0030705,
umls-concept:C0036043,
umls-concept:C0178602,
umls-concept:C0181586,
umls-concept:C0205179,
umls-concept:C0301630,
umls-concept:C0332183,
umls-concept:C0600688,
umls-concept:C1176020,
umls-concept:C1556095
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-4
|
|
pubmed:abstractText |
The effects of sunitinib in a broad patient population, especially those of Asian ethnicity, have been rarely investigated. Here, we assessed the efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
pubmed-author:AhnHanjongH,
pubmed-author:AhnJin-HeeJH,
pubmed-author:HongBumsikB,
pubmed-author:HongJun HyukJH,
pubmed-author:KimChoung-SooCS,
pubmed-author:KimJeong EunJE,
pubmed-author:LeeDae HoDH,
pubmed-author:LeeJae-LyunJL,
pubmed-author:LeeJung-ShinJS,
pubmed-author:NaShinS,
pubmed-author:SongCherynC,
pubmed-author:YooChanghoonC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
980-5
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20457723-Adult,
pubmed-meshheading:20457723-Aged,
pubmed-meshheading:20457723-Aged, 80 and over,
pubmed-meshheading:20457723-Anemia,
pubmed-meshheading:20457723-Antineoplastic Agents,
pubmed-meshheading:20457723-Asian Continental Ancestry Group,
pubmed-meshheading:20457723-Carcinoma, Renal Cell,
pubmed-meshheading:20457723-Dose-Response Relationship, Drug,
pubmed-meshheading:20457723-Fatigue,
pubmed-meshheading:20457723-Female,
pubmed-meshheading:20457723-Follow-Up Studies,
pubmed-meshheading:20457723-Humans,
pubmed-meshheading:20457723-Indoles,
pubmed-meshheading:20457723-Kaplan-Meier Estimate,
pubmed-meshheading:20457723-Kidney Neoplasms,
pubmed-meshheading:20457723-Male,
pubmed-meshheading:20457723-Middle Aged,
pubmed-meshheading:20457723-Neoplasm Staging,
pubmed-meshheading:20457723-Pyrroles,
pubmed-meshheading:20457723-Republic of Korea,
pubmed-meshheading:20457723-Thrombocytopenia,
pubmed-meshheading:20457723-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
|
|
pubmed:affiliation |
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
